Compounded GLP-1 Crisis: What Patients and Policymakers Need to Know

Overview of the Regulatory Action

The compounded GLP-1 receptor agonist controversy represents one of the most consequential pharmaceutical compliance disputes of the past decade, implicating drug shortage law, compounding pharmacy oversight, and consumer safety enforcement simultaneously. As reported by the Partnership for Safe Medicines, a coalition focused on drug safety and counterfeit prevention, the compounding of semaglutide and tirzepatide-based products has moved from a shortage-driven stopgap measure to a persistent gray-market phenomenon that continues even after the U.S. Food and Drug Administration (FDA) formally declared the shortages resolved.

The FDA removed tirzepatide (the active ingredient in Eli Lilly's Zepbound and Mounjaro) from its drug shortage database in December 2024, followed by semaglutide (the active ingredient in Novo Nordisk's Ozempic and Wegovy) in February 2025. Under federal law, this determination should have triggered a wind-down of mass compounding of these medications by both 503A pharmacies and 503B outsourcing facilities. Instead, litigation, market demand, and ambiguous compliance timelines have allowed compounded versions to remain widely available, often through telehealth platforms and med spas operating at the periphery of traditional pharmacy practice.

Legal Framework and Authority

The legal architecture governing this issue rests primarily on two provisions of the Federal Food, Drug, and Cosmetic Act (FDCA): Section 503A (21 U.S.C. § 353a) and Section 503B (21 U.S.C. § 353b), both added by the Drug Quality and Security Act of 2013 in response to the 2012 New England Compounding Center meningitis outbreak that killed over 100 patients.

Section 503A governs traditional compounding pharmacies that prepare patient-specific prescriptions and are exempt from FDA's new drug approval and manufacturing requirements, provided they do not compound "essentially a copy" of a commercially available FDA-approved drug. Section 503B permits larger outsourcing facilities to compound in bulk without individual prescriptions, subject to more rigorous current Good Manufacturing Practice (cGMP) oversight, but only under specific conditions—chief among them, that the compounded drug appears on FDA's drug shortage list or falls under other narrow exceptions.

When FDA lists a drug's active ingredient as being in shortage, both 503A and 503B facilities gain temporary latitude to produce compounded versions of that drug, even if it is commercially available, because the shortage itself justifies deviation from the "essentially a copy" prohibition. Once FDA removes the ingredient from the shortage list, however, that legal safe harbor closes. FDA guidance has generally allowed 503B facilities a short transition period and 503A pharmacies continued limited authority only when compounding for individualized patient needs, such as documented allergies to inactive ingredients or medically necessary alternative dosage forms—not simply cost or convenience.

Compounders challenged the shortage removals in court. The Outsourcing Facilities Association filed suit against FDA, arguing the agency's shortage resolution determination for tirzepatide was arbitrary and failed to account for continued supply gaps at the patient level. While courts have largely upheld FDA's shortage determinations, the litigation created interim uncertainty that some compounders and marketers have used to justify continued sales.

Industry Implications

The compounding dispute has fractured the peptide and pharmaceutical compounding industry along several lines. Legitimate 503B outsourcing facilities that complied with the wind-down timeline lost significant revenue streams built during the 2022–2024 shortage period, when compounded semaglutide and tirzepatide became a multi-billion-dollar market segment. Meanwhile, some operators—particularly telehealth-affiliated compounders and med spas—have continued distributing GLP-1 products, in some cases substituting salt forms such as semaglutide sodium or semaglutide acetate rather than the FDA-approved base compound.

FDA has explicitly warned that these salt forms are not the subject of an approved application and have not been demonstrated to be safe or effective, distinguishing them from legally compoundable versions of the approved active pharmaceutical ingredient. This has become a critical compliance flashpoint: manufacturers marketing salt-form GLP-1s may be operating entirely outside the 503A/503B framework, since these are arguably novel unapproved drugs rather than permissible compounds of an approved product.

Innovator companies Novo Nordisk and Eli Lilly have pursued an aggressive litigation strategy, filing dozens of lawsuits against compounding pharmacies, medical spas, and telehealth companies for trademark infringement, false advertising, and in some cases, distribution of drugs containing impurities or incorrect dosing concentrations. These suits function as a private enforcement supplement to FDA's more resource-constrained regulatory oversight.

Compliance Considerations

For compounding pharmacies and outsourcing facilities, the operative compliance question is whether continued production can be justified under the narrow patient-specific exceptions in Section 503A, such as documented clinical necessity for a different strength, dosage form, or formulation without a particular inactive ingredient. Blanket compounding to meet price-sensitive consumer demand does not meet this standard, and FDA has signaled through warning letters that it views such practices as unlawful.

State boards of pharmacy retain concurrent jurisdiction over 503A compounders and have begun issuing their own enforcement actions, creating a patchwork of oversight that varies significantly by state. Compounders must also contend with quality control challenges, including active pharmaceutical ingredient sourcing from overseas API manufacturers not subject to FDA facility inspection, a concern the agency has flagged in connection with adverse event reports involving dosing errors and contamination.

Patients face their own compliance and safety exposure. FDA's adverse event reporting system has logged thousands of reports associated with compounded GLP-1 products, including dosing confusion tied to variable concentrations across compounders, a risk that does not exist with the standardized, pre-filled pens of approved products.

Looking Ahead

Several developments will shape this landscape going forward. Continued litigation, including potential appeals in the Outsourcing Facilities Association case, may further clarify FDA's legal authority to terminate shortage-based compounding exemptions. Congress could also intervene; lawmakers have floated legislation to tighten compounding oversight or, conversely, to codify patient access protections if commercial GLP-1 pricing remains a barrier to care.

FDA enforcement priorities will likely focus on unapproved salt forms and telehealth-facilitated distribution channels, areas where the agency has already issued warning letters. Policymakers and stakeholders should watch for potential new guidance clarifying the boundaries of permissible patient-specific compounding under Section 503A now that both shortages have been formally resolved.

This analysis references reporting from the Partnership for Safe Medicines. Readers should consult FDA's official drug shortage database and compounding guidance documents for the most current regulatory status, as this remains an actively evolving area of law.